Tackling The High Rejection Rate For Invented Names In The EU
Executive Summary
Despite a revamp of the EU guideline on choosing a brand name for a new drug, more names continue to be rejected than accepted. The Pink Sheet’s Ian Schofield spoke to Alexios Skarlatos, the chair of the Name Review Group at the European Medicines Agency, and Jose Ferrero, a scientific administrator at the agency, to find out why and what can be done to improve things. It’s a lot more complex than you might think.